[go: up one dir, main page]

NO963366D0 - Peptider og fremgangsmåte for behandling av diabetes - Google Patents

Peptider og fremgangsmåte for behandling av diabetes

Info

Publication number
NO963366D0
NO963366D0 NO963366A NO963366A NO963366D0 NO 963366 D0 NO963366 D0 NO 963366D0 NO 963366 A NO963366 A NO 963366A NO 963366 A NO963366 A NO 963366A NO 963366 D0 NO963366 D0 NO 963366D0
Authority
NO
Norway
Prior art keywords
peptides
treating diabetes
diabetes
treating
Prior art date
Application number
NO963366A
Other languages
English (en)
Other versions
NO963366L (no
Inventor
Richard J Albertini
Michael T Falta
Original Assignee
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont filed Critical Univ Vermont
Publication of NO963366D0 publication Critical patent/NO963366D0/no
Publication of NO963366L publication Critical patent/NO963366L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ecology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
NO963366A 1994-02-14 1996-08-13 Peptider og fremgangsmåte for behandling av diabetes NO963366L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/195,963 US6113903A (en) 1989-03-21 1994-02-14 Peptides and methods against diabetes
PCT/US1995/001572 WO1995021623A1 (en) 1994-02-14 1995-02-10 Peptides and methods against diabetes

Publications (2)

Publication Number Publication Date
NO963366D0 true NO963366D0 (no) 1996-08-13
NO963366L NO963366L (no) 1996-10-14

Family

ID=22723558

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963366A NO963366L (no) 1994-02-14 1996-08-13 Peptider og fremgangsmåte for behandling av diabetes

Country Status (10)

Country Link
US (1) US6113903A (no)
EP (1) EP0744956A1 (no)
JP (1) JPH10501210A (no)
KR (1) KR100280220B1 (no)
AU (1) AU690234B2 (no)
CA (1) CA2182978A1 (no)
FI (1) FI963164A7 (no)
NO (1) NO963366L (no)
NZ (1) NZ282118A (no)
WO (1) WO1995021623A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008303A1 (en) * 1995-08-30 1997-03-06 University Technologies International Inc. Transgenic animals expressing diabetogenic t-cell receptor transgenes
US6054292A (en) * 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
WO2001085154A2 (en) * 2000-05-12 2001-11-15 Oregon Health Sciences University Method of treating immune pathologies with low dose estrogen
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US7790690B2 (en) 2000-10-11 2010-09-07 U.S. Department Of Veterans Affairs Glucose sensitive regulator of insulin transcription
US20030100056A1 (en) * 2000-12-22 2003-05-29 Anneli Attersand Protein cluster II
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7375211B2 (en) * 2005-11-18 2008-05-20 Kou Zhong C Method for detection and quantification of T-cell receptor Vβ repertoire

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066510A (en) * 1976-05-24 1978-01-03 Massachusetts Institute Of Technology Assay for mutagenesis in diploid human lymphoblasts
US4544632A (en) * 1981-06-12 1985-10-01 Yuichi Yamamura Human T cell lines and method of producing same
US4647535A (en) * 1981-08-12 1987-03-03 Research Corporation Human nonsecretory plasmacytoid cell line
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
WO1987003600A1 (en) * 1985-12-03 1987-06-18 T Cell Sciences, Inc. Cell-free t cell antigen receptor and its clinical utilities
US5112735A (en) * 1987-06-22 1992-05-12 University Of Vermont Detection of lymphocyte amplification
AU633251B2 (en) * 1988-02-03 1993-01-28 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
FI891226L (fi) * 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
DE69031919T3 (de) * 1989-07-19 2005-01-27 Connetics Corp., Palo Alto T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
CA2101065A1 (en) * 1991-01-22 1992-07-23 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof

Also Published As

Publication number Publication date
NO963366L (no) 1996-10-14
AU1912895A (en) 1995-08-29
KR100280220B1 (ko) 2001-02-01
WO1995021623A1 (en) 1995-08-17
FI963164L (fi) 1996-10-07
FI963164A0 (fi) 1996-08-13
CA2182978A1 (en) 1995-08-17
EP0744956A1 (en) 1996-12-04
AU690234B2 (en) 1998-04-23
JPH10501210A (ja) 1998-02-03
FI963164A7 (fi) 1996-10-07
NZ282118A (en) 1998-06-26
US6113903A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
NO970532D0 (no) System og metode for blodbehandling
NO951977D0 (no) Fremgangsmåte for lasting og behandling av hydrokarboner
NO963416L (no) Fremgangsmåte og anordning for gassbehandling
NO970543D0 (no) Fremgangsmåte og system for forutsigelse av blodbehandlingsparametere
DK1095941T3 (da) Fremgangsmåde og krystalformer for 2-methyl-thieno-benzodiazepin
NO981826L (no) Filterelement og fremgangsmÕte for fremstilling
NO20035726D0 (no) Benzopyran-inneholdende forbindelser og fremgangsmåte for anvendelse derav
FI973378A0 (fi) Laite ja menetelmä
NO980687L (no) System og fremgangsmåte for perfusjon-hypertermibehandling
PL324284A1 (en) Methods of treating diabetes
NO975759D0 (no) Inokuleringsmiddel og fremgangsmåte for fremstilling av inokuleringsmiddel
NO981108L (no) Freseapparat og fremgangsmÕte ved fresing
DE69424640D1 (de) Filmbehandlungsmethode und System
IS4805A (is) Aðferð til meðhöndlunar og lyfjasamsetning
NO980257D0 (no) Forankringsinnretning, og fremgangsmåte ved forankring
NO962482D0 (no) Anordning og fremgangsmåte ved behandling av organohalogen forbindelser
DK91793A (da) Fremgangsmåde til overfladebehandling, midler til udøvelse og anvendelsen heraf
NO992162D0 (no) FremgangsmÕte og innretning for rensing av blodplasma
FI932672L (fi) Menetelmä ja laite kuumien kaasujen käsittelemiseksi
NO993963D0 (no) Anordning og fremgangsmÕte til induksjonsforsegling
DE69514960D1 (de) Schlackbehandlungssystem und -methode
NO963366D0 (no) Peptider og fremgangsmåte for behandling av diabetes
NO177731C (no) F¶rprodukt og fremgangsmÕte for fremstilling av samme
NO963848D0 (no) Fremgangsmåte for diagnostisering og behandling av HIV-1-infeksjon
DE69717846D1 (de) Behandlungsverfahren von laktamen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application